

# Diego Ferone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3070760/publications.pdf>

Version: 2024-02-01

263  
papers

12,877  
citations

19608

61  
h-index

30848

102  
g-index

286  
all docs

286  
docs citations

286  
times ranked

8763  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length. <i>Pituitary</i> , 2022, 25, 246-257.	1.6	4
2	The effect of sodium restriction on iodine prophylaxis: a review. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1121-1138.	1.8	5
3	Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1465-1481.	1.8	6
4	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , 2022, 14, 2501.	1.7	7
5	Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4178-TPS4178.	0.8	1
6	Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. <i>Endocrine</i> , 2022, 77, 510-518.	1.1	10
7	Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. <i>European Journal of Endocrinology</i> , 2022, , .	1.9	4
8	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 563-579.	2.6	14
9	Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 327-337.	1.8	4
10	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021, 53, 367-374.	0.4	12
11	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). <i>Journal of Endocrinological Investigation</i> , 2021, 44, 989-994.	1.8	18
12	Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 789-801.	1.8	12
13	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021, 144, 200-214.	1.3	12
14	Vitamin D and Lung Outcomes in Elderly COVID-19 Patients. <i>Nutrients</i> , 2021, 13, 717.	1.7	61
15	A comparative cross-sectional study on sleep quality in patients with a history of differentiated thyroid carcinoma and its correlation with quality of life. <i>Endocrine</i> , 2021, 73, 347-357.	1.1	4
16	"Present and future of immunotherapy in Neuroendocrine Tumors". <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 615-636.	2.6	21
17	Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects. <i>Cancers</i> , 2021, 13, 1816.	1.7	5
18	Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. <i>Frontiers in Endocrinology</i> , 2021, 12, 677919.	1.5	16

#	ARTICLE	IF	CITATIONS
19	GH Replacement in the Elderly: Is It Worth It?. <i>Frontiers in Endocrinology</i> , 2021, 12, 680579.	1.5	6
20	Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge. <i>Endocrine Practice</i> , 2021, 27, 856-857.	1.1	4
21	Comparative Diagnostic Performance of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) Kit for the Rapid Detection of SARS-CoV-2. <i>Pathogens</i> , 2021, 10, 1629.	1.2	2
22	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	1.8	32
23	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	1.8	207
24	Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 389-393.	1.8	1
25	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2317-2324.	0.9	0
26	Efficacy of a novel second-generation somatostatin-dopamine chimera (TBR-065) in human medullary thyroid cancer: a preclinical study. <i>Neuroendocrinology</i> , 2020, 111, 937-950.	1.2	4
27	Emerging drugs for the treatment of acromegaly. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 409-417.	1.0	1
28	&lt;p&gt;Octreotide-Resistant Acromegaly: Challenges and Solutions&lt;/p&gt;. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 379-391.	0.9	16
29	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , 2020, 69, 441-450.	1.1	26
30	Somatostatin receptor expression and patientsâ€™ response to targeted medical treatment in pituitary tumors: evidences and controversies. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1543-1553.	1.8	18
31	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1094-1095.	2.8	6
32	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020, 25, 259-265.	1.9	27
33	Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3940.	1.8	26
34	Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019, 20, 365-381.	2.6	16
35	Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse. <i>Therapie</i> , 2019, 74, 547-549.	0.6	4
36	Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. <i>Pituitary</i> , 2019, 22, 552-560.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 375-385.	1.1	18
38	Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. <i>Pituitary</i> , 2019, 22, 89-99.	1.6	16
39	The primary role of radiological imaging in the diagnosis of rare musculoskeletal diseases. Emphasis on ultrasound. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ, SzopiÅ, ska</i> , 2019, 19, 187-192.	0.7	1
40	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , 2018, 62, 215-233.	1.1	21
41	Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up. , 2018, , 203-222.		0
42	Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS). <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1259-1266.	1.8	9
43	Hormone receptors analysis in idiopathic progressive subglottic stenosis. <i>Laryngoscope</i> , 2018, 128, E72-E77.	1.1	24
44	Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. <i>Endocrine</i> , 2018, 61, 533-541.	1.1	24
45	CTLA-4 gene variant -1661A&gt;G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61.	1.3	22
46	One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients. <i>Endocrine</i> , 2017, 55, 573-581.	1.1	11
47	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. <i>Endocrine</i> , 2017, 58, 349-359.	1.1	77
48	Long-term safety and efficacy of OmnitropeÅ® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 669-678.	1.8	5
49	Somatostatin receptor ligands in the treatment of acromegaly. <i>Pituitary</i> , 2017, 20, 100-108.	1.6	91
50	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017, 105, 245-254.	1.2	122
51	Prognostic factors in ectopic CushingÅ™s syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 453-461.	1.9	66
52	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. <i>Neuroendocrinology</i> , 2017, 105, 201-211.	1.2	127
53	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2454-2464.	1.8	51
54	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2009-2018.	1.8	54

#	ARTICLE	IF	CITATIONS
55	KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?. <i>Endocrine</i> , 2017, 57, 494-502.	1.1	18
56	Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. <i>Endocrine-Related Cancer</i> , 2017, 24, 505-518.	1.6	164
57	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , 2017, 57, 366-375.	1.1	33
58	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017, 24, 495-504.	1.6	61
59	Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. <i>Endocrine</i> , 2017, 57, 214-219.	1.1	81
60	Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas. <i>Molecular Neurobiology</i> , 2017, 54, 4879-4895.	1.9	57
61	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , 2017, 56, 633-638.	1.1	30
62	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1265-1269.	1.8	4
63	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. <i>Oncotarget</i> , 2017, 8, 41044-41063.	0.8	24
64	Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?. <i>Endocrine</i> , 2016, 53, 58-62.	1.1	18
65	Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor. <i>Neuroendocrinology</i> , 2016, 103, 452-459.	1.2	62
66	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. <i>Endocrine-Related Cancer</i> , 2016, 23, 871-881.	1.6	82
67	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 651-662.	1.9	40
68	Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. <i>Endocrine</i> , 2016, 53, 551-557.	1.1	8
69	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016, 103, 139-143.	1.2	241
70	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016, 103, 119-124.	1.2	380
71	Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. <i>Endocrine</i> , 2016, 51, 524-533.	1.1	11
72	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , 2016, 51, 131-139.	1.1	40

#	ARTICLE	IF	CITATIONS
73	Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (Hypo<scp>CCS</scp>) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. <i>Clinical Endocrinology</i> , 2015, 83, 527-535.	1.2	3
74	Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. <i>Archives of Endocrinology and Metabolism</i> , 2015, 59, 554-558.	0.3	4
75	Pituitary image: pituicytoma. <i>Pituitary</i> , 2015, 18, 592-597.	1.6	21
76	Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors. <i>Frontiers of Hormone Research</i> , 2015, 44, 216-238.	1.0	2
77	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015, 26, 1604-1620.	0.6	514
78	Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives. <i>Annales D'Endocrinologie</i> , 2015, 76, 43-58.	0.6	17
79	Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?. <i>Pituitary</i> , 2015, 18, 583-591.	1.6	39
80	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. <i>European Journal of Endocrinology</i> , 2015, 172, R227-R239.	1.9	114
81	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3231-3244.	1.8	113
82	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 193-259.	1.8	11
83	Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone (GH) replacement therapy in adults with GH deficiency. <i>Hormones</i> , 2014, 14, 134-41.	0.9	4
84	Diabetes Secondary to Neuroendocrine Gastroenteropancreatic Tumors. <i>Frontiers in Diabetes</i> , 2014, , 64-76.	0.4	3
85	Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-16.	0.6	18
86	Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. <i>European Journal of Endocrinology</i> , 2014, 170, 247-254.	1.9	15
87	Zebrafish as an innovative model for neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, R67-R83.	1.6	38
88	Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. <i>Drug Discovery Today</i> , 2014, 19, 458-468.	3.2	31
89	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , 2014, 46, 181-198.	1.1	27
90	Managing Cushing's disease: the state of the art. <i>Endocrine</i> , 2014, 47, 9-20.	1.1	54

#	ARTICLE	IF	CITATIONS
91	Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 860-870.	1.6	15
92	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. <i>Endocrine-Related Cancer</i> , 2014, 21, 691-704.	1.6	53
93	Ectopic Cushing and Other Paraneoplastic Syndromes in Thoracic Neuroendocrine Tumors. <i>Thoracic Surgery Clinics</i> , 2014, 24, 277-283.	0.4	16
94	In memory of Francesco Maria Minuto. <i>Growth Hormone and IGF Research</i> , 2014, 24, 155-156.	0.5	0
95	The Metabolic Profile in Active Acromegaly is Gender-Specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E51-E59.	1.8	54
96	Le terapie combinate nell'acromegalia: pro e contro. <i>L'Endocrinologo</i> , 2013, 14, 71-78.	0.0	0
97	Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency. <i>European Journal of Endocrinology</i> , 2013, 169, 767-772.	1.9	80
98	Î²-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients With Acromegaly. <i>Endocrinology</i> , 2013, 154, 4715-4725.	1.4	54
99	Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E66-E71.	1.8	129
100	Diabetic Hepatosclerosis Presenting With Severe Cholestasis. <i>Diabetes Care</i> , 2013, 36, e206-e206.	4.3	8
101	Interactions between vitamin D and IGF: from physiology to clinical practice. <i>Clinical Endocrinology</i> , 2013, 79, 457-463.	1.2	76
102	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. <i>Clinical Endocrinology</i> , 2013, 79, 211-216.	1.2	11
103	Somatostatin receptor pathophysiology in the neuroendocrine system. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 149-157.	1.2	3
104	Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression. <i>Current Molecular Medicine</i> , 2013, 13, 555-571.	0.6	27
105	Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 38-43.	1.8	55
106	Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What's New?. <i>Neuroendocrinology</i> , 2012, 95, 267-276.	1.2	51
107	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E165-E172.	1.8	41
108	Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 613-615.	1.8	12

#	ARTICLE	IF	CITATIONS
109	Everolimus is an active agent in medullary thyroid cancer: a clinical and <i>in vitro</i> study. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1563-1572.	1.6	42
110	Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. <i>Pituitary</i> , 2012, 15, 209-214.	1.6	7
111	Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. <i>Pituitary</i> , 2012, 15, 215-221.	1.6	8
112	Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. <i>Clinical Endocrinology</i> , 2012, 76, 407-414.	1.2	47
113	Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 326-31.	1.8	44
114	Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the <i>in vivo</i> visualization during somatostatin receptor scintigraphy. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 528-34.	1.8	11
115	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 817-23.	1.8	64
116	Italian Society of Endocrinology Career Award Lecture: from somatostatin to somatomedin. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 869-74.	1.8	0
117	Identification of a novel mutation in exon 1 of androgen receptor gene in an azoospermic patient with mild androgen insensitivity syndrome: case report and literature review. <i>Fertility and Sterility</i> , 2011, 96, 1165-1169.	0.5	23
118	Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. <i>Journal of Zhejiang University: Science B</i> , 2011, 12, 163-173.	1.3	20
119	<i>In vivo</i> and <i>in vitro</i> response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. <i>Pituitary</i> , 2011, 14, 141-147.	1.6	40
120	Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. <i>Radiologia Medica</i> , 2011, 116, 781-792.	4.7	13
121	Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. <i>European Journal of Endocrinology</i> , 2011, 164, 335-340.	1.9	11
122	2. Somatostatin and dopamine receptors. <i>Tumori</i> , 2010, 96, 802-805.	0.6	7
123	Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. <i>Journal of Endocrinology</i> , 2010, 207, 309-317.	1.2	29
124	Role of Dopamine Receptors in Normal and Tumoral Pituitary Corticotropic Cells and Adrenal Cells. <i>Neuroendocrinology</i> , 2010, 92, 17-22.	1.2	14
125	Primary empty sella: Why and when to investigate hypothalamic-pituitary function. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 343-346.	1.8	40
126	Regulation of prostate cancer cell proliferation by somatostatin receptor activation. <i>Molecular and Cellular Endocrinology</i> , 2010, 315, 254-262.	1.6	24



#	ARTICLE	IF	CITATIONS
127	High prevalence of vitamin D deficiency and its association with left ventricular dilation: An echocardiography study in elderly patients with chronic heart failure. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 633-640.	1.1	68
128	Somatostatin and dopamine receptors. <i>Tumori</i> , 2010, 96, 802-5.	0.6	1
129	The clinicalâ€“molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. <i>Journal of Molecular Endocrinology</i> , 2009, 42, 361-370.	1.1	66
130	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy. <i>Neuroendocrinology</i> , 2009, 90, 209-213.	1.2	64
131	Computed Tomography Colonography in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 218-222.	1.8	17
132	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. <i>Acta Diabetologica</i> , 2009, 46, 85-95.	1.2	119
133	Ultrasound of peripheral nerves in acromegaly: changes at 1â€“year followâ€“up. <i>Clinical Endocrinology</i> , 2009, 71, 220-225.	1.2	25
134	Significant tumour shrinkage after 12â€“months of lanreotide Autogelâ€“120â€“mg treatment given firstâ€“line in acromegaly. <i>Clinical Endocrinology</i> , 2009, 71, 237-245.	1.2	64
135	Institutional experience of PTH evaluation on fine-needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. <i>Journal of Zhejiang University: Science B</i> , 2009, 10, 323-330.	1.3	28
136	Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 308-312.	1.8	21
137	Peptide receptor therapies in neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 360-369.	1.8	104
138	Effect of environment on growth: Auxological and hormonal parameters in African and Italian children. <i>Growth Hormone and IGF Research</i> , 2009, 19, 238-241.	0.5	4
139	Sonographic Depiction of Trigger Fingers in Acromegaly. <i>Journal of Ultrasound in Medicine</i> , 2009, 28, 1441-1446.	0.8	16
140	Somatostatin receptor expression in thymic tumors. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 3304.	3.0	7
141	Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. <i>Pituitary</i> , 2008, 11, 93-102.	1.6	50
142	Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study. <i>Thyroid Research</i> , 2008, 1, 2.	0.7	15
143	A Unique Association of Clinical "Persistent Mullerian Duct Syndrome" and Syringoid Carcinoma of the Perineal-Scrotal Skin: A Consequence of Urologic Surgery?. <i>Journal of Andrology</i> , 2008, 29, 15-19.	2.0	0
144	Leptin, Ghrelin, and Adiponectin Evaluation in Transsexual Subjects During Hormonal Treatments. <i>Journal of Andrology</i> , 2008, 29, 580-585.	2.0	15

#	ARTICLE	IF	CITATIONS
145	Chapter 8 Autoimmunity and the Pituitary Gland. Handbook of Systemic Autoimmune Diseases, 2008, 9, 83-93.	0.1	0
146	Sympathovagal imbalance in transsexual subjects. Journal of Endocrinological Investigation, 2008, 31, 1014-1019.	1.8	4
147	Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. Journal of Endocrinological Investigation, 2008, 31, 352-359.	1.8	3
148	Normal age-dependent values of serum insulin growth factor-I: Results from a healthy Italian population. Journal of Endocrinological Investigation, 2008, 31, 445-449.	1.8	42
149	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Colon and Rectum Tumour/Carcinoma. Neuroendocrinology, 2008, 87, 31-39.	1.2	104
150	The pathology of the ulnar nerve in acromegaly. European Journal of Endocrinology, 2008, 159, 369-373.	1.9	25
151	Overexpression of Stromal Cell-Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas. Clinical Cancer Research, 2008, 14, 5022-5032.	3.2	104
152	Ultrasound Measurement of Median and Ulnar Nerve Cross-Sectional Area in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 905-909.	1.8	57
153	Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases. Kidney International, 2008, 74, 937-945.	2.6	27
154	Correlation of in Vitro and in Vivo Somatotrophic Adenoma Responsiveness to Somatostatin Analogs and Dopamine Agonists with Immunohistochemical Evaluation of Somatostatin and Dopamine Receptors and Electron Microscopy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1412-1417.	1.8	114
155	Replacement therapy and cardiovascular diseases. Journal of Endocrinological Investigation, 2008, 31, 85-90.	1.8	6
156	The Association of Fasting Insulin Concentrations and Colonic Neoplasms in Acromegaly: A Colonoscopy-Based Study in 210 Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3854-3860.	1.8	56
157	Rapid Pituitary Tumor Shrinkage with Dissociation between Antiproliferative and Antisecretory Effects of a Long-Acting Octreotide in an Acromegalic Patient. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1592-1599.	1.8	77
158	Evidence of Prolonged Orocecal Transit Time and Small Intestinal Bacterial Overgrowth in Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2119-2124.	1.8	40
159	Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 65-69.	1.8	67
160	Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. European Journal of Endocrinology, 2007, 156, S37-S43.	1.9	21
161	Novel chimeric somatostatin analogs: facts and perspectives. European Journal of Endocrinology, 2007, 156, S23-S28.	1.9	38
162	Pegvisomant in acromegaly: Why, when, how. Journal of Endocrinological Investigation, 2007, 30, 693-699.	1.8	35

#	ARTICLE	IF	CITATIONS
163	Somatostatin receptor scintigraphy in thoracic diseases. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 889-902.	1.8	12
164	Serum osteoprotegerin and soluble receptor activator of nuclear factor $\kappa$ B ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. <i>Metabolism: Clinical and Experimental</i> , 2007, 56, 699-707.	1.5	9
165	Novel insights in dopamine receptor physiology. <i>European Journal of Endocrinology</i> , 2007, 156, S13-S21.	1.9	114
166	Lack of Somatostatin Analogs Effectiveness in Gonadotropin-Secreting Pituitary Adenomas. , 2006, 16, 208-213.		1
167	Neuroendocrine-Immune Interactions: The Role of Cortistatin/Somatostatin System. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 129-144.	1.8	43
168	Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. <i>Neuroendocrinology</i> , 2006, 84, 183-188.	1.2	248
169	Sympathovagal Imbalance in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 115-120.	1.8	29
170	Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease. <i>European Journal of Endocrinology</i> , 2006, 154, 813-818.	1.9	38
171	Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients. <i>Clinical Endocrinology</i> , 2005, 63, 294-297.	1.2	5
172	Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 289, E1044-E1050.	1.8	44
173	Cabergoline plus Lanreotide for Ectopic Cushing's Syndrome. <i>New England Journal of Medicine</i> , 2005, 352, 2457-2458.	13.9	78
174	Initial Staging of Lymphoma With Octreotide and Other Receptor Imaging Agents. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 176-185.	2.5	27
175	Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 166-169.	1.8	11
176	Potential indications for somatostatin analogues: immune system and limphoproliferative disorders. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 111-7.	1.8	8
177	Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4493-4502.	1.8	70
178	Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2452-2462.	1.8	246
179	Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. <i>Clinical Endocrinology</i> , 2004, 61, 138-144.	1.2	39
180	Cost-of-illness study in acromegalic patients in Italy. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 1034-1039.	1.8	45

#	ARTICLE	IF	CITATIONS
181	Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. <i>Endocrine Reviews</i> , 2004, 25, 102-152.	8.9	1,093
182	Somatostatin receptor distribution and function in immune system. <i>Digestive and Liver Disease</i> , 2004, 36, S68-S77.	0.4	40
183	The role of somatostatin receptors in the medical treatment of acromegaly. <i>Digestive and Liver Disease</i> , 2004, 36, S55-S59.	0.4	8
184	Somatostatin Control of Immune Functions. , 2004, , 193-206.		0
185	Current diagnostic guidelines for biochemical diagnosis of acromegaly. <i>Minerva Endocrinologica</i> , 2004, 29, 207-23.	1.7	7
186	In Vivo and In Vitro Detection of Dopamine D2 Receptors in Uveal Melanomas. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 895-902.	0.7	9
187	The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 94-102.	1.8	2
188	The role of somatostatin analogs in the management of immunoproliferative disease. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 103-8.	1.8	2
189	Acromegaly and immune function. <i>NeuroImmune Biology</i> , 2002, , 247-257.	0.2	3
190	Lymphocyte subset pattern in acromegaly. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 125-128.	1.8	21
191	Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E1056-E1066.	1.8	61
192	99m Technetium penta-valent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. <i>Clinical Endocrinology</i> , 2002, 56, 713-721.	1.2	7
193	In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 522-528.	1.8	20
194	In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: Correlation with somatostatin and dopamine D2 receptor scintigraphy. <i>Clinical Endocrinology</i> , 2001, 54, 469-477.	1.2	29
195	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , 2001, 54, 97-106.	1.2	7
196	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001, 54, 515-524.	1.2	101
197	Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2779-2786.	1.8	242
198	Neuroendocrine aspects of immunolymphoproliferative diseases. <i>Annals of Oncology</i> , 2001, 12, S125-S130.	0.6	10

#	ARTICLE	IF	CITATIONS
199	Is the Acromegalic Cardiomyopathy Reversible? Effect of 5-Year Normalization of Growth Hormone and Insulin-Like Growth Factor I Levels on Cardiac Performance*. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1551-1557.	1.8	102
200	Title is missing!. Annals of Oncology, 2001, 12, 125-130.	0.6	6
201	Physiological and pathophysiological role of somatostatin receptors in the human thymus. European Journal of Endocrinology, 2000, 143 Suppl 1, S27-S34.	1.9	27
202	Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. European Journal of Endocrinology, 2000, 143 Suppl 1, S35-S42.	1.9	8
203	Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123 I-methoxybenzamide. Clinical Endocrinology, 2000, 52, 437-445.	1.2	52
204	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clinical Endocrinology, 2000, 53, 13-19.	1.2	52
205	Age-related decrease of somatostatin receptor number in the normal human thymus. American Journal of Physiology - Endocrinology and Metabolism, 2000, 279, E791-E798.	1.8	24
206	Somatostatin Receptor Subtypes in Human Thymoma and Inhibition of Cell Proliferation by Octreotide In Vitro. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1719-1726.	1.8	59
207	Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy<sup>1</sup>. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 193-199.	1.8	154
208	Cardiac Effect of Thyrotoxicosis in Acromegaly<sup>1</sup>. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1426-1432.	1.8	17
209	Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients<sup>1</sup>. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3754-3761.	1.8	38
210	Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4099-4103.	1.8	99
211	Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3132-3140.	1.8	95
212	Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?. Drugs and Aging, 2000, 17, 81-92.	1.3	30
213	Impact of Patient's Age and Disease Duration on Cardiac Performance in Acromegaly: A Radionuclide Angiography Study. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1518-1523.	1.8	71
214	Endoscopic Endonasal Transsphenoidal Approach: An Additional Reason in Support of Surgery in the Management of Pituitary Lesions. Skull Base, 1999, 9, 109-117.	0.4	86
215	Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2664-2672.	1.8	344
216	In Vitro Characterization of Somatostatin Receptors in the Human Thymus and Effects of Somatostatin and Octreotide on Cultured Thymic Epithelial Cells. Endocrinology, 1999, 140, 373-380.	1.4	95

#	ARTICLE	IF	CITATIONS
217	Effects of 1-Year Treatment with Octreotide on Cardiac Performance in Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 17-23.	1.8	115
218	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1986-1991.	1.8	67
219	Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. <i>Clinical Endocrinology</i> , 1999, 51, 159-164.	1.2	21
220	Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. <i>Clinical Endocrinology</i> , 1999, 51, 611-618.	1.2	64
221	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999, 1, 115-120.	1.6	81
222	The pituitary uptake of <sup>111</sup> In-DTPA-D-Phe <sup>1</sup> -octreotide in the normal pituitary and in pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 176-183.	1.8	42
223	Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 40-47.	1.8	65
224	Somatostatin receptors in the thymus. <i>Annals of Medicine</i> , 1999, 31 Suppl 2, 28-33.	1.5	4
225	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 1998, 49, 77-84.	1.2	13
226	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. <i>Journal of Urology</i> , 1998, 160, 1583-1584.	0.2	0
227	Height, weight, height velocity of primary school population sample in Campania region. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 142-147.	1.8	6
228	Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 257-262.	1.8	4
229	Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 284-290.	1.8	72
230	Bone mineral density and circulating cytokines in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 688-693.	1.8	33
231	Correlation of Scintigraphic Results Using <sup>123</sup> I-Methoxybenzamide with Hormone Levels and Tumor Size Response to Quinagolide in Patients with Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 248-252.	1.8	36
232	Orbital Scintigraphy with [ <sup>111</sup> In-Diethylenetriamine Pentaacetic Acid-D-Phe <sup>1</sup> ]-Octreotide Predicts the Clinical Response to Corticosteroid Therapy in Patients with Graves' Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3790-3794.	1.8	43
233	Reversibility of Joint Thickening in Acromegalic Patients: An Ultrasonography Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2121-2125.	1.8	70
234	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 775-779.	1.8	94

#	ARTICLE	IF	CITATIONS
235	Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. <i>European Journal of Endocrinology</i> , 1998, 138, 286-293.	1.9	111
236	Effect of Different Dopaminergic Agents in the Treatment of Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 518-523.	1.8	140
237	Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 876-883.	1.8	219
238	Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3308-3314.	1.8	199
239	Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2777-2781.	1.8	130
240	Effect of Growth Hormone on Cardiac Function. <i>Hormone Research</i> , 1997, 48, 38-42.	1.8	51
241	Failure of long-term therapy with sodium valproate in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 387-392.	1.8	33
242	Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 513-518.	1.8	3
243	Fixity of vocal cords and laryngocele in acromegaly. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 672-674.	1.8	11
244	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. <i>Clinical Endocrinology</i> , 1997, 47, 23-28.	1.2	89
245	Acute administration of hexarelin stimulates GH secretion during day and night in normal men. <i>Clinical Endocrinology</i> , 1997, 46, 275-279.	1.2	2
246	Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. <i>Journal of Endocrinology</i> , 1997, 155 Suppl 1, S33-7; discussion S39.	1.2	19
247	Cardiovascular aspects in acromegaly: Effects of treatment. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 57-60.	1.5	41
248	Tumor Necrosis Factor-Alpha Increases after Corticotropin-Releasing Hormone Administration in Cushing's Disease. <i>Neuroendocrinology</i> , 1996, 64, 393-397.	1.2	9
249	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. <i>Clinical Endocrinology</i> , 1996, 45, 157-166.	1.2	11
250	Corticotropin Releasing Hormone Administration Increases Alpha-Melanocyte-Stimulating Hormone Levels in the Inferior Petrosal Sinuses in a Subset of Patients with Cushing's Disease. <i>Hormone Research</i> , 1996, 46, 26-32.	1.8	5
251	Prediction of efficacy of octreotide therapy in patients with acromegaly.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2356-2362.	1.8	126
252	Comparison among Different Dopamine-Agonists of New Formulation in the Clinical Management of Macroprolactinomas. <i>Hormone Research</i> , 1995, 44, 222-228.	1.8	21

#	ARTICLE	IF	CITATIONS
253	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. <i>Gynecological Endocrinology</i> , 1995, 9, 15-21.	0.7	7
254	Technetium-99m penta-valent dimercaptosuccinic acid imaging in patients with pituitary adenomas. <i>European Journal of Endocrinology</i> , 1995, 133, 38-47.	1.9	10
255	CV 205-502 treatment in therapy-resistant acromegalic patients. <i>European Journal of Endocrinology</i> , 1995, 132, 559-564.	1.9	32
256	Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. <i>European Journal of Endocrinology</i> , 1995, 133, 189-194.	1.9	10
257	Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. <i>Gynecological Endocrinology</i> , 1994, 8, 175-181.	0.7	25
258	Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. <i>European Journal of Endocrinology</i> , 1994, 131, 14-19.	1.9	9
259	Hypothalamic-Pituitary-Adrenal Axis in Neuropsychiatric Disorders. <i>Annals of the New York Academy of Sciences</i> , 1994, 741, 263-270.	1.8	11
260	Effects of a Chronic Treatment with Octreotide in Patients with Functionless Pituitary Adenomas. <i>Hormone Research</i> , 1993, 40, 149-155.	1.8	29
261	Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 77, 790-793.	1.8	105
262	Further Evaluation of IGF-I Responsiveness to ACTH in Children Affected with IGHD. <i>Hormone Research</i> , 1992, 38, 150-153.	1.8	2
263	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. , 0, .		23